• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Clinical validation of quantitative SARS-CoV-2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs

tetano

Editor, Senior Moderator
J Infect Chemother


. 2020 Dec 3;S1341-321X(20)30428-1.
doi: 10.1016/j.jiac.2020.11.021. Online ahead of print.
Clinical validation of quantitative SARS-CoV-2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs


Kotaro Aoki[SUP] 1 [/SUP], Tatsuya Nagasawa[SUP] 1 [/SUP], Yoshikazu Ishii[SUP] 2 [/SUP], Shintaro Yagi[SUP] 3 [/SUP], Sadatsugu Okuma[SUP] 3 [/SUP], Katsuhito Kashiwagi[SUP] 4 [/SUP], Tadashi Maeda[SUP] 4 [/SUP], Taito Miyazaki[SUP] 4 [/SUP], Sadako Yoshizawa[SUP] 1 [/SUP], Kazuhiro Tateda[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Expansion of the testing capacity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important issue to mitigate the pandemic of coronavirus disease-2019 (COVID-19) caused by this virus. Recently, a sensitive quantitative antigen test (SQT), Lumipulse? SARS-CoV-2 Ag, was developed. It is a fully automated chemiluminescent enzyme immunoassay system for SARS-CoV-2.
Methods: In this study, the analytical performance of SQT was examined using clinical specimens from nasopharyngeal swabs using reverse transcription polymerase chain reaction (RT-PCR) as a control.
Results: Receiver operating characteristic analysis of 24 SARS-CoV-2-positive and 524 -negative patients showed an area under the curve of 0.957 ? 0.063. Using a cut-off value of 1.34 pg/ml, the sensitivity was 91.7%, the specificity was 98.5%, and the overall rate of agreement was 98.2%. In the distribution of negative cases, the 99.5 percentile value was 1.03 pg/ml. There was a high correlation between the viral load calculated using the cycle threshold value of RT-PCR and the concentration of antigen. The tendency for the antigen concentration to decrease with time after disease onset correlated with that of the viral load.
Conclusions: Presented results indicate that SQT is highly concordant with RT-PCR and should be useful for the diagnosis of COVID-19 in any clinical setting. Therefore, this fully automated kit will contribute to the expansion of the testing capability for SARS-CoV-2.

Keywords: Chemiluminescent enzyme immunoassay; Covid-19; Nasopharyngeal swab; Nasopharynx; SARS-CoV-2; Saliva; Sensitive quantitative antigen test.
 
Back
Top Bottom